Pan-RAS molecular glue posts 62% response rates in NSCLC Phase 1, but a patent war with Revolution Medicines could halt development before Phase 3 begins

Bull

A positive outcome would see Erasca successfully initiate the Phase 3 trial — implying either a favorable resolution of the RevMed patent dispute, a design-around, or a court ruling that the claims are invalid or not infringed — validating that the 62% unconfirmed ORR and clean safety profile from Phase 1 can be pursued in a registrational setting. This would confirm the pan-RAS molecular glue mechanism is clinically and legally defensible, substantially de-risking the program and supporting a high-value partnering or commercialization pathway in a large KRAS-mutant NSCLC patient population.

Bear

The most likely failure mode is that the Revolution Medicines litigation results in a preliminary injunction or binding legal determination that forces a halt to ERAS-0015 development before the Phase 3 can enroll, rendering the strong Phase 1 data commercially irrelevant. Even absent an injunction, protracted litigation could delay trial initiation well beyond the planned window, erode investor confidence, and force costly design modifications or licensing terms that dilute the program's value; additionally, if expanded Phase 1 cohort data show the initial 62% ORR was inflated by unconfirmed responses that fail confirmation, the registrational rationale could weaken.